PepGen Inc.
NASDAQ:PEPG
Overview | Financials
| Company Name | PepGen Inc. |
| Symbol | PEPG |
| Currency | USD |
| Price | 1.49 |
| Market Cap | 48,871,590 |
| Dividend Yield | 0% |
| 52-week-range | 0.88 - 10.055 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. James G. McArthur Ph.D. |
| Website | https://www.pepgen.com |
An error occurred while fetching data.
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD







